
## **Catalog:** #2316

Store at: -20ºC

For Research Use Only. Not For Use In Diagnostic Procedures.


<b>Applications</b> Flow Cytometry	<b>Detection</b> Anti-Rabbit IgG	<b>Clonality</b> Monoclonal	<b>lsotype</b> Rabbit IgGk			
Format:	Unconjugated		, j			
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.					
Formulation:	1X PBS, 0.02% NaN3, 50% Glycerol, 0	1% BSA				
Preparation:	Protein A+G					
Reactivity:	Human,Mouse					
Recommended Usage:	1μg/mL – 0.001μg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.					
Immunogen:	A synthetic phospho-peptide correspo human phospho c-Cbl	nding to residues surroun	ding Tyr774 of			
Description:	The c-Cbl (Casitas B-lineage Lymphoma) proto-oncogene is a ubiquitously expressed cytoplasmic adaptor protein that contains multiple functional domains, including an amino-terminal tyrosine kinase-binding (TKB) domain, a RING finger motif, and a proline-rich region. The TKB recognizes phosphorylated tyrosines on activated receptor tyrosine kinases (RTKs) and on other nonreceptor tyrosine kinases, while the RING finger motif recruits ubiquitin-conjugating enzymes. These two domains are primarily responsible for the ubiquitin ligase activity of c-Cbl and downregulation of RTKs (1). The proline-rich region contains 14-3-3 protein-binding and SH3 domain-binding motifs. c-Cbl is phosphorylated at Y700, Y731, and Y774 by Syk- and Src-family kinases after the stimulation of some integrins and a wide variety of receptors for immunoglobulins, antigens, hormones, growth factors, and cytokines. Phosphorylated Y774 interacts with the SH2 domain of Crk (1,2). The c-Cbl adapter protein is expressed in the cytoplasm in all tissues, with especially high levels of expression in hematopoietic cells (3,4). Through its many functional sites, c-Cbl plays key roles in the positive and negative regulation of vital cell functions, including T Cell Receptor-mediated cellular immune responses. In human cancer tissues, c-Cbl is frequently tyrosine-phosphorylated in a tumor-specific manner (5).					
References:	1. Christine, B.F. et al. (2001) Nat. Rev 2. Feshchenko, E.A. et al. (1998) J. Bio 3. Blake, T.J. et al. (1991) Oncogene. 6 4. Thien, C.B. and Langdon, W.Y. (199 5. Kamei, T. et al. (2000) Int. J. Oncol.	l. Chem. 273: 8323-8331. 5: 653-657. 8) Immunol. Cell Biol. 76:				






lgG	Treatment	Peptide Block	Median : BL1-A
R3B8	IFN	Non-phos.	83984
R3B8	Ctrl	Non-phos.	958
R3B8	IFN	Phospho	725
R3B8	Ctrl	Phospho	420
R3B8	IFN	-	77948
R3B8	Ctrl	-	980
2' only	Ctrl	-	376

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or treated with  $IFN\alpha + IL-4 + pervanadate$  (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-c-Cbl (Tyr774) antibody CblY774-R3B8 at 0.1 µg/mL. Cat. #2316.



Flow cytometric analysis of 3T3 cells secondary antibody only negative control (blue) or untreated (gray) or treated with IFN $\alpha$  + IL-4 + pervanadate (orange) using 0.1 µg/mL isotype control Cat. #2141 or untreated (red) or treated (green) using Phospho-c-Cbl (Tyr774) antibody CblY774-R3B8 at 0.01 µg/mL. Cat. #2316.





Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN $\alpha$  + IL-4 + pervanadate (green) using Phospho-c-Cbl (Tyr774) antibody CblY774-R3B8 at 0.01 µg/mL. Cat. #2316.

